Rodin Therapeutics Inc.
Epigenetic agents for treating cognitive disorders
This article was originally published in Start Up
Epigenetics continues to be a hot experimental field, but few drugs for modifying gene transcription to control cell-cycle progression have been tried out for central nervous system disorders despite scientific evidence linking aberrant epigenetic processes to several neurodegenerative conditions. Rodin Therapeutics Inc. is stepping in by bringing together international expertise in structural biology with CNS drug development leadership to discover and develop epigenetic agents for Alzheimer’s disease and other CNS disorders.
You may also be interested in...
Epigenetics-focused company believes a selective HDAC2 inhibitor could provide a safe way to treat signs and symptoms of Alzheimer’s. Having raised $12.9 million in Series A funding, Rodin hopes to move from lead optimization to clinical development over the next 18 to 24 months.
The reorientation of Big Pharma neuroscience R&D toward a biology-driven approach is creating new hope for the treatment of psychiatric disorders.
Alzheimer’s disease science is in disarray and the risk associated with developing disease-modifying agents has driven many players from the field. But venturesome biotechs are finding backers to support efforts to look for a way forward: we profile Alzheon Inc., Neurotrack Inc., Rodin Therapeutics Inc., and Tetra Discovery Partners LLC.